In a phase II study, the combination regimen of selumetinib and docetaxel showed an increased median PFS of 5.3 and ORR of 37%,72 whereas in a follow‐up randomized phase III (SELECT‐1) study, combining selumetinib with docetaxel did not improve the OS and PFS of KRAS‐mutant NSCLC patients, compared with docetaxel.73 Here, KRAS is linked to non-small cell lung carcinoma.